 |
CEDAR RAPIDS, Iowa, January 5/PRNewswire/ -- RepHresh Vaginal Gel has been approved as a Class IIa medical device for the prevention and treatment of bacterial vaginosis (BV) in the EU. Its patent-protected formula adheres to the vaginal epithelium for 3 days per use, normalizing pH to a healthy 4.5 or less. BV cannot develop in a vaginal environment with a pH of 4.5 or less. It is the only product of its kind available without a prescription.
Many women assume that vaginal discomforts stem primarily from yeast infections. In fact, nearly half of all vaginal infections are BV, a result of bacterial overgrowth in the vagina.
"Bacterial vaginosis symptoms are similar to those of yeast infections -- itching, burning, dryness or soreness and general vaginal discomfort," said Dr. Machelle M. Seibel, Professor of Obstetrics and Gynecology at the University of Massachusetts.
In a study published by the American Journal of Obstetrics and Gynecology, women tested for genital complaints had the following incidence rates:
- 46% Bacterial Vaginosis
- 29% Yeast Infection
- 25% Chlamydia/Trichomoniasis/Other
"It's easy for women to confuse yeast infections with BV," said Dr. Seibel. "However, while yeast infections usually aren't risky, BV increases the risk of pre-term birth, early miscarriage, acquiring sexually transmitted diseases, and pelvic inflammatory disease."
RepHresh is safe for long-term use for women who are pregnant, suffer from recurrent BV, or who have had hysterectomies -- a group prone to vaginal infection.
"We are pleased to have gained approval for this product. It will help millions of women improve their vaginal health," said Giacomo Tormene, President & Managing Director for Lil' Drug Store International. "We anticipate a strong response from physicians, pharmacists and consumers throughout the world."
Lil' Drug Store Products, headquartered in Cedar Rapids, Iowa - USA, is a privately held company, and is the maker of RepHresh. Lil' Drug Store has its European offices in Maastricht, the Netherlands. According to Mr. Tormene, the company seeks new distribution partners in the EU and worldwide, in addition to their current network.
Public relations, physician/pharmacist education, and consumer sampling programs are planned for the second quarter of 2006.
For further information contact:
Steve Bosking, Lil' Drug Store Products'
Director of Marketing at sbosking@lildrugstore.com or phone +1-319-393-0454
Media Contact:
Suzy Ginsburg - +1-713-721-4774 or suzy@gcomworks.com
Source: Lil' Drug Store Products
|
